Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidaseGRABOWSKI, Brian; KHOSRAVAN, Reza; WU, Jing-Tao et al.British journal of clinical pharmacology. 2010, Vol 70, Num 1, pp 57-64, issn 0306-5251, 8 p.Article

Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjectsKHORSAVAN, Reza; GRABOWSKI, Brian; WU, Jing-Tao et al.British journal of clinical pharmacology. 2008, Vol 65, Num 3, pp 355-363, issn 0306-5251, 9 p.Article

Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjectsKHOSRAVAN, Reza; GRABOWSKI, Brian A; WU, Jing-Tao et al.Clinical pharmacokinetics. 2006, Vol 45, Num 8, pp 821-841, issn 0312-5963, 21 p.Article

Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic-Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK InhibitorWONG, Harvey; VERNILLET, Laurent; HOEFLICH, Klaus P et al.Clinical cancer research (Print). 2012, Vol 18, Num 11, pp 3090-3099, issn 1078-0432, 10 p.Article

Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumorsGELMON, Karen A; LATREILLE, Jean; BESENVAL, Michele et al.Journal of clinical oncology. 2000, Vol 18, Num 24, pp 4098-4108, issn 0732-183XArticle

Results of a phase Ila study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutationCLANCY, J. P; ROWE, Steven M; DE BOECK, Kris et al.Thorax. 2012, Vol 67, Num 1, pp 12-18, issn 0040-6376, 7 p.Article

Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase A twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with goutBECKER, Michael A; RALPH SCHUMACHER, H. JR; WORTMANN, Robert L et al.Arthritis and rheumatism. 2005, Vol 52, Num 3, pp 916-923, issn 0004-3591, 8 p.Article

Interplay of Dissolution, Solubility, and Nonsink Permeation Determines the Oral Absorption of the Hedgehog Pathway Inhibitor GDC-0449 in Dogs: An Investigation Using Preclinical Studies and Physiologically Based Pharmacokinetic ModelingWONG, Harvey; THEIL, Frank-Peter; YUZHONG DENG et al.Drug metabolism and disposition. 2010, Vol 38, Num 7, pp 1029-1038, issn 0090-9556, 10 p.Article

A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancersTRENT, Jonathan C; VALERO, Vicente; CRISTOFANILLI, Massimo et al.Clinical cancer research. 2003, Vol 9, Num 7, pp 2426-2434, issn 1078-0432, 9 p.Article